Feeds › Clinical trial updates
Clinical trial updates
Drug and device trials that companies register on ClinicalTrials.gov: newly completed phase 3 studies, changes of status and the dates a study is due to finish.
About this data
- What it is
- ClinicalTrials.gov is the US registry of clinical studies. Drug and device makers register their trials there and update the record as each study moves on. We list the studies that companies sponsor, and match the sponsor to a public company when the name lines up. The page opens on Phase 3 studies marked completed, the late-stage trials that come before a request for approval. Change View to see the changes of status we have noticed, or every recent update.
- Who files it
- The sponsor of the study, in its record on ClinicalTrials.gov. The registry is run by the US National Library of Medicine and does not check what sponsors report.
- How current
- We check the registry every day. Sponsors update records on their own schedule, from the same week to months later, so a change can appear in the registry well after it happened.
- Terms
- ClinicalTrials.govClinicalTrials.gov is the US government's registry of clinical studies, run by the National Library of Medicine. Sponsors register a study before it starts and update the record as it goes. The registry does not check what a sponsor reports.Phase 3The late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages.statusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time).completedThe sponsor has marked the study as finished. It says nothing about whether the treatment worked: results, if any, are reported separately and often later.status changesOur history of status changes starts the day we first stored each study, so a change made before that is not shown. The date is when we noticed the change, which can be later than when the sponsor made it.primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update.company matchWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private.
- Worth knowing
- A completed study is not a result: the registry says the study ended, not whether the treatment worked. Status changes start on the day we first stored each study, so earlier changes are not shown. Dates are the sponsor's own, and an estimated date can pass without an update. We match sponsors to companies automatically, with a hand-checked list for the large drugmakers, so a study with no ticker may still belong to a public company. This is information about studies, not a forecast of what they will show or of a stock's price.
- Not to be confused with
- FDA approvals and clearances: what the FDA decided, not what a sponsor reports about a study.
All of this comes from ClinicalTrials.gov, the US registry of clinical studies. We are not affiliated with it.
Source and freshness · Information, not investment advice (disclaimer).
Studies updated per day, last 30 days
All industry-sponsored studies Sponsor matched to a public company
By the day the sponsor last updated the study's record. A study updated twice counts once, on its latest day.
Latest clinical trial updates
Showing: ticker ONC · All recent updates
Studies by the date their record was last updated.
| Updated | Study | SponsorWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private. | PhaseThe late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages. | StatusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time). | Enrolled | Primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update. | Source |
|---|---|---|---|---|---|---|---|
| Nov 12, 2026 | A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Food Effect of… NCT07934069 · Healthy Participants BON-107, Placebo | ONC BeOne Medicines | Phase 1 | Not yet recruiting | 100 | Oct 11, 2027 | Registry ↗ |
| Nov 12, 2026 | An Investigational Study of BG-75202 Alone and in Combination With Other Agents in Adults With Adva… NCT07222267 · Breast Cancer, Advanced Solid Tumor BG-75202, CDK4 Inhibitor | ONC BeOne Medicines | Phase 1 | Recruiting | 186 | Sep 30, 2029 | Registry ↗ |
| Nov 12, 2026 | A Study of Tacabrutideg (BGB-16673) Compared to Investigator's Choice in Participants With Chronic… NCT06846671 · CLL, Chronic Lymphocytic Leukemia Tacabrutideg, Bendamustine | ONC BeOne Medicines | Phase 3 | Recruiting | 250 | May 15, 2028 | Registry ↗ |
| Nov 10, 2026 | Study Comparing BGB-B2033 With Sorafenib or Lenvatinib in Advanced Hepatocellular Carcinoma NCT07836530 · Hepatocellular Carcinoma, Liver Cancer BGB-B2033, Lenvatinib | ONC BeOne Medicines | Phase 3 | Recruiting was not yet recruiting | 492 | Sep 21, 2029 | Registry ↗ |
| Nov 4, 2026 | A Study to Investigate Safety, Tolerability, and Pharmacokinetics of Tacabrutideg (BGB-16673) in Pa… NCT07856004 · Hepatic Impairment, Healthy Adult Participants Tacabrutideg | ONC BeOne Medicines | Phase 1 | Not yet recruiting | 24 | Jul 31, 2027 | Registry ↗ |
| Nov 3, 2026 | Study Evaluating the Efficacy and Safety of BGB-B2033 in Participants With Advanced Hepatocellular… NCT07911683 · Hepatocellular Cancer, Liver Cancer BGB-B2033 | ONC BeOne Medicines | Phase 2 | Not yet recruiting | 100 | Mar 31, 2028 | Registry ↗ |
| Oct 29, 2026 | A Study of BON-C1393 in Adults With Advanced Solid Tumors NCT07904845 · Solid Tumors, Advanced Solid Tumors BON-C1393, Bevacizumab | ONC BeOne Medicines | Phase 1 | Not yet recruiting | 90 | Feb 27, 2029 | Registry ↗ |
| Oct 29, 2026 | A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Place… NCT06742996 · Mantle Cell Lymphoma, B Cell Lymphoma Sonrotoclax, Zanubrutinib | ONC BeOne Medicines | Phase 3 | Recruiting | 300 | Aug 31, 2028 | Registry ↗ |
| Oct 28, 2026 | A Study of BG-C477 in Participants With Advanced Solid Tumors NCT06596473 · Advanced Solid Tumors BG-C477, Tislelizumab | ONC BeOne Medicines | Phase 1 | Recruiting | 310 | Jul 23, 2028 | Registry ↗ |
| Oct 27, 2026 | A First-in-Human Study of BG-92505 Alone or in Combination With Other Anti-cancer Agents in Patient… NCT07896460 · Advanced Solid Tumor BG-92505, Anti-Cancer Agent | ONC BeOne Medicines | Phase 1 | Not yet recruiting | 137 | Aug 29, 2028 | Registry ↗ |
| Oct 26, 2026 | An Investigational Study of BON-106 in Adults With Advanced or Metastatic Solid Tumors NCT07893535 · Solid Tumor, Advanced Solid Tumor BON-106 | ONC BeOne Medicines | Phase 1 | Not yet recruiting | 96 | Dec 2030 | Registry ↗ |
| Oct 26, 2026 | A Study of Sonrotoclax (BGB-11417) in Children With Relapsed or Refractory Acute Myeloid Leukemia a… NCT07770698 · Relapsed Acute Myeloid Leukemia, Refractory Acute Myeloid L… sonrotoclax, Azacitidine | ONC BeOne Medicines | Phase 1/2 | Not yet recruiting | 30 | Apr 30, 2030 | Registry ↗ |
| Oct 26, 2026 | A Study Investigating Alternate Schedules of Tislelizumab Plus Chemotherapy in Japanese Patients Wi… NCT07733180 · Advanced Esophageal Squamous Cell Carcinoma, Metastatic Eso… Tislelizumab, Oxaliplatin | ONC BeOne Medicines | Phase 2 | Recruiting | 30 | Feb 28, 2028 | Registry ↗ |
| Oct 26, 2026 | BGB-43395 Plus Letrozole Versus CDK4/6i Plus Letrozole for Patients With Advanced or Metastatic HR+… NCT07492641 · HR+/HER2- Breast Cancer BGB-43395, Letrozole | ONC BeOne Medicines | Phase 3 | Recruiting | 1,056 | Apr 2029 | Registry ↗ |
| Oct 26, 2026 | A Study to Investigate the Safety of Novel Dose Ramp-up Schedule(s) When Initiating Sonrotoclax in… NCT06697184 · Chronic Lymphocytic Leukemia, CLL Sonrotoclax, Zanubrutinib | ONC BeOne Medicines | Phase 1/2 | Recruiting | 258 | Nov 30, 2029 | Registry ↗ |
| Oct 26, 2026 | A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexam… NCT04973605 · Relapsed/Refractory Multiple Myeloma Sonrotoclax, Dexamethasone | ONC BeOne Medicines | Phase 1/2 | Recruiting | 246 | Nov 2026 | Registry ↗ |
| Oct 23, 2026 | A Trial in Healthy Participants to Assess Drug Interaction Potential of BGB-43395 NCT07820891 · Healthy Adult Participants BGB-43395, Midazolam | ONC BeOne Medicines | Phase 1 | Recruiting | 24 | Nov 22, 2026 | Registry ↗ |
| Oct 23, 2026 | A First-in-Human Study Investigating BG-85738 Alone or in Combination With Other Antitumor Agents i… NCT07746141 · RAS Mutation, Advanced Solid Tumor BG-85738, Tislelizumab | ONC BeOne Medicines | Phase 1 | Recruiting | 100 | Sep 30, 2028 | Registry ↗ |
| Oct 23, 2026 | A Study to Investigate the Relative Bioavailability and Food Effect of Tablet for Oral Suspension o… NCT07628881 · Healthy Volunteers Sonrotoclax Tablet for Oral Suspension, Sonrotoclax Tablet | ONC BeOne Medicines | Phase 1 | Completed | 12 | Sep 26, 2026 | Registry ↗ |
| Oct 23, 2026 | A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax… NCT06943872 · Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma Sonrotoclax, Obinutuzumab | ONC BeOne Medicines | Phase 3 | Recruiting | 630 | Sep 30, 2029 | Registry ↗ |
| Oct 21, 2026 | A Study Investigating the Safety and How the Trispecific T-Cell Engaging Antibody BG-T0920 Works in… NCT07887646 · Diffuse Large B-Cell Lymphoma, B-cell Malignancies BG-T0920 | ONC BeOne Medicines | Phase 1 | Not yet recruiting | 70 | Oct 31, 2029 | Registry ↗ |
| Oct 21, 2026 | Treatment of Chinese Participants With B-Cell Malignancies With BGB-16673, a Bruton Tyrosine Kinase… NCT05294731 · B-cell Malignancy, Non-Hodgkin Lymphoma Tacabrutideg | ONC BeOne Medicines | Phase 1/2 | Recruiting | 146 | Jun 30, 2027 | Registry ↗ |
| Oct 20, 2026 | A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Sonrotoclax in Participant… NCT07855991 · Hepatic Impairment, Healthy Adult Participants Sonrotoclax | ONC BeOne Medicines | Phase 1 | Not yet recruiting | 12 | Feb 8, 2027 | Registry ↗ |
| Oct 20, 2026 | An Investigational Study of BGB-58067 As a Single Agent and in Combination With Anticancer Agents i… NCT06589596 · Advanced Solid Tumor BGB-58067, BG-89894 | ONC BeOne Medicines | Phase 1 | Recruiting | 695 | Aug 31, 2028 | Registry ↗ |
| Oct 20, 2026 | A Study to Investigate Efficacy and Safety of BCL2 Inhibitor Sonrotoclax as Monotherapy and in Comb… NCT05952037 · Waldenstrom Macroglobulinemia, Waldenstrom's Macroglobuline… Sonrotoclax, Zanubrutinib | ONC BeOne Medicines | Phase 2 | Active, not recruiting | 114 | Sep 22, 2026 | Registry ↗ |
| Oct 19, 2026 | A Study Investigating the Safety and How the Trispecific T-Cell Engaging Antibody BG-T0050 Works in… NCT07881211 · Diffuse Large B-Cell Lymphoma, B-Cell Malignancies BG-T0050 | ONC BeOne Medicines | Phase 1 | Not yet recruiting | 70 | Oct 31, 2029 | Registry ↗ |
| Oct 16, 2026 | A Study to Evaluate Efficacy and Safety of Tislelizumab Plus Chemotherapy for Locally Advanced Unre… NCT07554521 · Advanced Unresectable Gastric Adenocarcinoma, Esophageal Sq… Tislelizumab, Capecitabine | ONC BeOne Medicines | Phase 2 | Recruiting | 30 | Dec 31, 2031 | Registry ↗ |
| Oct 15, 2026 | A Study to Investigate Treatment Patterns and Effectiveness of Tislelizumab in European Patients Wi… NCT07652736 · Advanced Non-Small Cell Lung Cancer, Extensive-Stage Small… Tislelizumab | ONC BeOne Medicines | — | Recruiting | 440 | Nov 15, 2027 | Registry ↗ |
| Oct 15, 2026 | BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Ad… NCT06120283 · Advanced Solid Tumor, Advanced Breast Cancer BGB-43395, Fulvestrant | ONC BeOne Medicines | Phase 1 | Recruiting | 433 | Dec 2029 | Registry ↗ |
| Oct 15, 2026 | A Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants With Rela… NCT05100862 · Relapsed/Refractory Follicular Lymphoma, Marginal Zone Lymp… Zanubrutinib, Rituximab | ONC BeOne Medicines | Phase 3 | Active, not recruiting | 799 | Jul 2028 | Registry ↗ |
| Oct 14, 2026 | A Study to Investigate Tislelizumab Administered as Subcutaneous Injection Versus Intravenous Infus… NCT07043400 · Metastatic Gastric Adenocarcinoma, Gastroesophageal Junctio… Subcutaneous Tislelizumab, Intravenous Tislelizumab | ONC BeOne Medicines | Phase 3 | Recruiting | 351 | Oct 30, 2027 | Registry ↗ |
| Oct 14, 2026 | Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutu… NCT06073821 · CLL Sonrotoclax, Zanubrutinib | ONC BeOne Medicines | Phase 3 | Active, not recruiting | 652 | Feb 2032 | Registry ↗ |
| Oct 9, 2026 | A Study to Investigate the Effect of the CYP3A Inducer Phenytoin and the CYP3A Inhibitor Itraconazo… NCT07590102 · Healthy Volunteers BGB-58067, Phenytoin | ONC BeOne Medicines | Phase 1 | Recruiting | 30 | Oct 31, 2026 | Registry ↗ |
| Oct 5, 2026 | A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malig… NCT05006716 · B-cell Malignancy, Marginal Zone Lymphoma Tacabrutideg | ONC BeOne Medicines | Phase 1/2 | Recruiting | 689 | Mar 2027 | Registry ↗ |
| Sep 30, 2026 | A Study to Investigate the Efficacy of Zanubrutinib Plus Rituximab Compared With Bendamustine Plus… NCT04002297 · Mantle Cell Lymphoma; Non-Hodgkin Lymphoma zanubrutinib, bendamustine | ONC BeOne Medicines | Phase 3 | Active, not recruiting | 510 | Apr 27, 2026 | Registry ↗ |
| Sep 28, 2026 | A Study to Investigate the Relative Bioavailability of 2 Tablet Formulations and the Effect of Food… NCT07712640 · Healthy Volunteers BGB-58067 Tablet (F-01 Formulation), BGB-58067 Tablet (F-02… | ONC BeOne Medicines | Phase 1 | Recruiting | 32 | Jul 1, 2027 | Registry ↗ |
| Sep 28, 2026 | An Investigational Study of BG-75202 Alone and in Combination With Other Agents in Patients With My… NCT07619287 · Myeloid Malignancy BG-75202, Hypomethylation Agent (HMA) | ONC BeOne Medicines | Phase 1 | Recruiting | 118 | Sep 30, 2028 | Registry ↗ |
| Sep 28, 2026 | A First-in-Human Study of BG-C0979 in Adults With Advanced Solid Tumors NCT07414836 · Advanced Solid Tumor BG-C0979, Tislelizumab | ONC BeOne Medicines | Phase 1 | Recruiting | 84 | Apr 30, 2029 | Registry ↗ |
| Sep 28, 2026 | A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetocla… NCT07277231 · Chronic Lymphocytic Leukemia Sonrotoclax, Zanubrutinib | ONC BeOne Medicines | Phase 3 | Recruiting | 500 | Feb 2031 | Registry ↗ |
| Sep 28, 2026 | A Study of BG-75098 Alone and in Combination With Other Agents in Adults With Advanced Solid Tumors NCT07226349 · Advanced Solid Tumor BG-75098, BGB-43395 | ONC BeOne Medicines | Phase 1 | Recruiting | 105 | Nov 1, 2028 | Registry ↗ |
| Sep 28, 2026 | A First-in-Human Study of BG-C0902 Alone and in Combination With Other Therapeutic Agents in Patien… NCT07181681 · Solid Tumors, Advanced Solid Tumor BG-C0902 | ONC BeOne Medicines | Phase 1 | Recruiting | 63 | Nov 1, 2027 | Registry ↗ |
| Sep 28, 2026 | A Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib i… NCT06973187 · Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma Tacabrutideg, Pirtobrutinib | ONC BeOne Medicines | Phase 3 | Recruiting | 500 | Apr 17, 2028 | Registry ↗ |
| Sep 28, 2026 | A Study Investigating BGB-26808 Alone or in Combination With Tislelizumab in Participants With Adva… NCT05981703 · Advanced Solid Tumor, Solid Tumor BGB-26808, Tislelizumab | ONC BeOne Medicines | Phase 1 | Recruiting | 337 | Feb 28, 2029 | Registry ↗ |
| Sep 22, 2026 | Study of Sonrotoclax (BGB-11417) Monotherapy in Participants With Relapsed or Refractory Mantle Cel… NCT05471843 · Mantle Cell Lymphoma, Refractory Mantle Cell Lymphoma (MCL) Sonrotoclax | ONC BeOne Medicines | Phase 1/2 | Active, not recruiting | 125 | Jul 18, 2025 | Registry ↗ |
| Sep 16, 2026 | A Phase 1/2 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizum… NCT06427941 · Metastatic Hepatocellular Carcinoma, Local Advanced Hepatoc… BGB-B2033, Tislelizumab | ONC BeOne Medicines | Phase 1/2 | Recruiting | 630 | Mar 31, 2027 | Registry ↗ |
| Sep 16, 2026 | Phase 1a/1b First-in-Human Study of BG-C9074 Alone and in Combination With Other Anticancer Therapi… NCT06233942 · Advanced Solid Tumor BG-C9074, Tislelizumab | ONC BeOne Medicines | Phase 1 | Recruiting | 308 | Sep 28, 2027 | Registry ↗ |
| Sep 14, 2026 | BGB-21447 (Bcl-2 Inhibitor) Combinations for Adults With Hormone-Receptor Positive (HR+)/Human Epid… NCT06756932 · Hormone-receptor-positive Breast Cancer, HER2-negative Brea… BGB-21447, Fulvestrant | ONC BeOne Medicines | Phase 1 | Recruiting | 120 | Jul 30, 2027 | Registry ↗ |
| Sep 14, 2026 | A Study of BGB-11417 in Participants With Myeloid Malignancies NCT04771130 · Acute Myeloid Leukemia, Myelodysplastic Syndromes BGB-11417, Azacitidine | ONC BeOne Medicines | Phase 1/2 | Recruiting | 260 | Aug 31, 2028 | Registry ↗ |
| Sep 11, 2026 | A Study to Investigate Safety and Effectiveness of Tacabrutideg (BGB-16673) in Combination With Oth… NCT06634589 · B-cell Malignancy, Relapsed Cancer Tacabrutideg, Sonrotoclax | ONC BeOne Medicines | Phase 1/2 | Recruiting | 80 | Dec 2, 2028 | Registry ↗ |
| Sep 11, 2026 | Study of BG-T187 Alone and in Combination With Other Therapeutic Agents in Participants With Advanc… NCT06598800 · Advanced Solid Tumor Drug: BG-T187, Other Therapeutic Agents | ONC BeOne Medicines | Phase 1 | Recruiting | 153 | Sep 30, 2028 | Registry ↗ |
The newest 50 items, most recent first. Each row links to the study's page on ClinicalTrials.gov. Updated Nov 15, 2026, 6:51 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · FDA approvals and clearances